News | May 16, 2025
Sanofi India posts 27% growth in operating profits in Q1 2025
Standalone profit from operations for the quarter were Rs. 162 crores
Standalone profit from operations for the quarter were Rs. 162 crores
_256_384.jpg)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
The transaction enhances Roquette’s ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide
The Q1 2025 also witnessed a successful launch of Allegra D
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Bayer expects 2025 to be the most difficult year of its turnaround
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Subscribe To Our Newsletter & Stay Updated
